[ad_1] Korea BMS Pharmaceuticals and Pfizer Korea announced that an oral anticoagulant Elyquis has been approved for use in remedies for the treatment of critically ill patients with atrial fibrillation requiring conversion …
Read More »Eliquez adds permission for treatment of patients with critical atrial fibrillation requiring conversion of cardioversion
